{"id":155893,"date":"2025-03-28T07:03:12","date_gmt":"2025-03-28T06:03:12","guid":{"rendered":"https:\/\/efecomunica.efe.com\/?p=155893"},"modified":"2025-03-28T11:12:48","modified_gmt":"2025-03-28T10:12:48","slug":"curium-completes-the-acquisition-of-monrol-as-part-of-its-plan-to-significantly-expand-lutetium-177-capacity-and-pet-footprint","status":"publish","type":"post","link":"https:\/\/efecomunica.efe.com\/en\/curium-completes-the-acquisition-of-monrol-as-part-of-its-plan-to-significantly-expand-lutetium-177-capacity-and-pet-footprint\/","title":{"rendered":"Curium completes the acquisition of Monrol as part of its plan to significantly expand Lutetium-177 capacity and PET footprint"},"content":{"rendered":"<p>Statement issued by the company (Announcement)<\/p>\n<div>\n<ul>\n<li>Positions Curium as leading manufacturer of Lu-177 isotope<\/li>\n<li>Brings innovative R&amp;D expertise and pipeline to Curium<\/li>\n<li>Enhances Curium\u2019s SPECT &amp; PET geographical coverage and supply chain<\/li>\n<\/ul>\n<p><strong>Curium Pharma<\/strong> (\u201cCurium\u201d), a world leader in nuclear medicine, is pleased to announce the completion of its acquisition of Eczac\u0131ba\u015f\u0131-Monrol Nuclear Products Co. (Monrol), a leading nuclear medicine player, which is headquartered in Istanbul, Turkey.<\/p>\n<p>The acquisition enhances Curium\u2019s manufacturing capacity of Lutetium-177 (Lu-177) to meet the growing demand for isotope around the world and secure the supply for the future launch of Curium\u2019s Lu-177 drug candidates, for <strong>Prostate Cancer<\/strong> (currently in development) and Neuroendocrine Tumours (pending approval).<\/p>\n<p>Monrol complements and adds to Curium\u2019s extensive research &amp; development (R&amp;D) capabilities as it continues to expand its portfolio and pipeline of innovative theranostic products. Curium intends to deploy Monrol\u2019s Ga-68 generator globally in the future, pending regulatory approvals.<\/p>\n<p>In addition, <strong>Monrol\u2019s PET &amp; SPECT<\/strong> complementary geographic footprint further expands Curium\u2019s offering. The completion of the deal expands Curium\u2019s PET footprint of 34 sites in Western Europe and Asia to 46 with the addition of 12 Monrol owned and partnered sites in Eastern Europe and MENA regions. Furthermore, Monrol\u2019s manufacturing and logistics infrastructure in Istanbul, Turkey, immediately adds scale to Curium\u2019s vertically integrated production and distribution capabilities.<\/p>\n<p>Mr. <strong>Chaitanya Tatineni<\/strong>, Curium\u2019s CEO International Markets commented: \u201cWe are delighted to welcome close to 400 highly-skilled and dedicated new colleagues to Curium Group. The coming together of Curium and Monrol will transform our scale, capabilities and reach across several critical areas, in particular Lu-177, and create multiple new opportunities to enhance our offering of life-changing diagnostic and therapeutic solutions to patients around the world.\u201d<\/p>\n<p>Mr. <strong>Aydin Kucuk<\/strong> General Manager at Monrol added: \u201cWe are excited to be joining Curium and have long admired the company\u2019s capabilities, leadership and commitment to developing and supplying world-class nuclear diagnostics solutions and therapies. We look forward to working with our new Curium colleagues to build on our joint successes to date by integrating our expertise, knowledge and experience with Curium\u2019s global footprint, product portfolio, and track record of innovation.\u201d<\/p>\n<p>Mr. <strong>Emin Fad\u0131ll\u0131o\u011flu,<\/strong> CEO, Eczac\u0131ba\u015f\u0131 Pharmaceutical and Industrial Investment, said: \u201cWe are very proud of our association with Monrol and its transformation in recent years, which today sees them become part of Curium, a world-leader in nuclear medicine. This is a great reflection of the quality of the business, and we believe they will continue to thrive under the ownership of Curium, benefiting from greater access to advanced technology and an extensive global network.\u201d<\/p>\n<pre><strong>For more information:<\/strong>\r\n\r\n<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=O97Va-4TgttO9pAJONo7h1Kre5dQ48FozZ70wc4cu3LbLxtSUnyy-k5v2yFBQb5vSdgwGmS2Chc03XfktkBHxyyB7G7ysbVgeBxtc4erBLxpTfUIhcc11F4_sv4ftZr5\" target=\"_blank\" rel=\"noopener\">communications@curiumpharma.com<\/a>\r\n\r\nor\r\n\r\nBen Valdimarsson\r\nReputation Inc\r\nMob: +44 (0)788 9805930\r\nEmail:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xw3jSLbD5ocqkucgw8mevgdXtBrYt2dhZaLvQo8ajPfeukDywPzQhgK5P3Kq_se2wTokbRJqDyCRLlSbFO1S5pxffOKEPRtX03xSEOuQE1IkpwbfDC8uqyDGKPKf0F4CoIf1zC13bw64h4qWcxLrdw==\" target=\"_blank\" rel=\"noopener\">bvaldimarsson@reputation-inc.com<\/a><\/pre>\n<h2>About Curium<\/h2>\n<p>Curium is a world leader in nuclear medicine. We develop, manufacture, and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence, and unparalleled service.<\/p>\n<p>With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name \u2018Curium\u2019 honors the legacy of pioneering radioactive materials researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. To learn more, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nH7Lezqum81Fhmg55gDq4kI7QUrdqa90jc3FHISde-ZDX_khFdTgBesSnCFASqomxqc5tZ3_6C5otrhurvecRbvtGgjCJYh8sfm27O7n7dk=\" target=\"_blank\" rel=\"noopener\">www.curiumpharma.com<\/a><\/p>\n<h2>About Monrol<\/h2>\n<p>Headquartered in Istanbul, Monrol is a nuclear medicine company leading innovation for the development and manufacturing of GMP grade radioisotopes and radiopharmaceuticals, Monrol distributes its world-class radiopharmaceutical products portfolio in global markets. As both a CMO and CDMO, Monrol provides early development support to customers and offers fully integrated services for nimble, lean, virtual companies taking new product concepts into clinical trials, demonstrating proof of concept, and going into first-in-human studies. Monrol is committed to transform and improve patient journey in cancer treatment through a portfolio of radiopharmaceutical products that it distributes to more than 60 countries around the globe. To learn more, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=K_Hm-gGW3S8guq1UIHE9al9_Xasgi7mBab6zLUzZYiOq5LE70_A7gAaKME_KlCZ3DssFUL3rat8GITD3pKZ-E5Tu-LOL8cOZV4LeNxv8qjNgo5LJhfQxS2x6v0r6dZN2FNMEGtBe4JWzZ308yH5uBAprXw4IHna7-b9Ev9ViiJXWF5wfmbGcxQFS--SGpHaC0fHRnwC1DMbYi3Z7_NL6DQPcopr6X7iz3-SLLHIVjNp7V3ANsKZaxPiqYIdd7aYDstvZUEGCrsT3D-LijR-5XW3gvKE2D9LoaJ5EFckG2OO--5OLlmnxeUHu1SAkS4TH\" target=\"_blank\" rel=\"noopener\">www.monrol.com<\/a>.<\/p>\n<p><img \/><em><img \/>AGENCIA EFE S.A.U.,S.M.E. shall not be liable for any information contained in this message and assumes no responsibility towards third parties in relation to its contents, being expressly exempt from any liability that the author may have in relation to the information in question. Agencia EFE reserves the right to distribute the press release on the news wire, or to publish it on EFE Comunica.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Statement issued by the company (Announcement) Positions Curium as leading manufacturer of Lu-177 isotope Brings innovative R&amp;D expertise and pipeline to Curium Enhances Curium\u2019s SPECT &amp; PET geographical coverage and [&hellip;]<\/p>\n","protected":false},"author":198164071,"featured_media":48434,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[121851],"tags":[],"class_list":["post-155893","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Curium completes the acquisition of Monrol<\/title>\n<meta name=\"description\" content=\"Curium completes the acquisition of Monrol as part of its plan to significantly expand Lutetium-177 capacity and PET footprint.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/efecomunica.efe.com\/en\/curium-completes-the-acquisition-of-monrol-as-part-of-its-plan-to-significantly-expand-lutetium-177-capacity-and-pet-footprint\/\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Curium completes the acquisition of Monrol","description":"Curium completes the acquisition of Monrol as part of its plan to significantly expand Lutetium-177 capacity and PET footprint.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/efecomunica.efe.com\/en\/curium-completes-the-acquisition-of-monrol-as-part-of-its-plan-to-significantly-expand-lutetium-177-capacity-and-pet-footprint\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/efecomunica.efe.com\/en\/curium-completes-the-acquisition-of-monrol-as-part-of-its-plan-to-significantly-expand-lutetium-177-capacity-and-pet-footprint\/#article","isPartOf":{"@id":"https:\/\/efecomunica.efe.com\/en\/curium-completes-the-acquisition-of-monrol-as-part-of-its-plan-to-significantly-expand-lutetium-177-capacity-and-pet-footprint\/"},"author":{"name":"EFE","@id":"https:\/\/efecomunica.efe.com\/#\/schema\/person\/38c335f1ce4cd42430576ef5499343b8"},"headline":"Curium completes the acquisition of Monrol as part of its plan to significantly expand Lutetium-177 capacity and PET footprint","datePublished":"2025-03-28T06:03:12+00:00","dateModified":"2025-03-28T10:12:48+00:00","mainEntityOfPage":{"@id":"https:\/\/efecomunica.efe.com\/en\/curium-completes-the-acquisition-of-monrol-as-part-of-its-plan-to-significantly-expand-lutetium-177-capacity-and-pet-footprint\/"},"wordCount":747,"publisher":{"@id":"https:\/\/efecomunica.efe.com\/#organization"},"image":{"@id":"https:\/\/efecomunica.efe.com\/en\/curium-completes-the-acquisition-of-monrol-as-part-of-its-plan-to-significantly-expand-lutetium-177-capacity-and-pet-footprint\/#primaryimage"},"thumbnailUrl":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/efecomunica.efe.com\/en\/curium-completes-the-acquisition-of-monrol-as-part-of-its-plan-to-significantly-expand-lutetium-177-capacity-and-pet-footprint\/","url":"https:\/\/efecomunica.efe.com\/en\/curium-completes-the-acquisition-of-monrol-as-part-of-its-plan-to-significantly-expand-lutetium-177-capacity-and-pet-footprint\/","name":"Curium completes the acquisition of Monrol","isPartOf":{"@id":"https:\/\/efecomunica.efe.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/efecomunica.efe.com\/en\/curium-completes-the-acquisition-of-monrol-as-part-of-its-plan-to-significantly-expand-lutetium-177-capacity-and-pet-footprint\/#primaryimage"},"image":{"@id":"https:\/\/efecomunica.efe.com\/en\/curium-completes-the-acquisition-of-monrol-as-part-of-its-plan-to-significantly-expand-lutetium-177-capacity-and-pet-footprint\/#primaryimage"},"thumbnailUrl":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","datePublished":"2025-03-28T06:03:12+00:00","dateModified":"2025-03-28T10:12:48+00:00","description":"Curium completes the acquisition of Monrol as part of its plan to significantly expand Lutetium-177 capacity and PET footprint.","breadcrumb":{"@id":"https:\/\/efecomunica.efe.com\/en\/curium-completes-the-acquisition-of-monrol-as-part-of-its-plan-to-significantly-expand-lutetium-177-capacity-and-pet-footprint\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/efecomunica.efe.com\/en\/curium-completes-the-acquisition-of-monrol-as-part-of-its-plan-to-significantly-expand-lutetium-177-capacity-and-pet-footprint\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/efecomunica.efe.com\/en\/curium-completes-the-acquisition-of-monrol-as-part-of-its-plan-to-significantly-expand-lutetium-177-capacity-and-pet-footprint\/#primaryimage","url":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","contentUrl":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","width":1200,"height":650,"caption":"El \u00edndice Moneyball de Squawka clasifica a los clubes de la Premier League tomando en cuenta las \u00faltimas cinco temporadas (incluida la 2025\/26)."},{"@type":"BreadcrumbList","@id":"https:\/\/efecomunica.efe.com\/en\/curium-completes-the-acquisition-of-monrol-as-part-of-its-plan-to-significantly-expand-lutetium-177-capacity-and-pet-footprint\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/efecomunica.efe.com\/"},{"@type":"ListItem","position":2,"name":"Curium completes the acquisition of Monrol as part of its plan to significantly expand Lutetium-177 capacity and PET footprint"}]},{"@type":"WebSite","@id":"https:\/\/efecomunica.efe.com\/#website","url":"https:\/\/efecomunica.efe.com\/","name":"EFE Comunica","description":"Contenidos para empresas","publisher":{"@id":"https:\/\/efecomunica.efe.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/efecomunica.efe.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/efecomunica.efe.com\/#organization","name":"EFE Comunica","url":"https:\/\/efecomunica.efe.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/efecomunica.efe.com\/#\/schema\/logo\/image\/","url":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2020\/12\/Logo-EFE-Comunica_png.png","contentUrl":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2020\/12\/Logo-EFE-Comunica_png.png","width":1080,"height":486,"caption":"EFE Comunica"},"image":{"@id":"https:\/\/efecomunica.efe.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/EFEComunicaAgenciaEFE","https:\/\/x.com\/EFEcomunica","https:\/\/www.linkedin.com\/showcase\/efecomunica"]},{"@type":"Person","@id":"https:\/\/efecomunica.efe.com\/#\/schema\/person\/38c335f1ce4cd42430576ef5499343b8","name":"EFE","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e5fcf26bedbd04dc20896c519164a13fe69c6913f5830d7db51543fa04eb30b4?s=96&d=identicon&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e5fcf26bedbd04dc20896c519164a13fe69c6913f5830d7db51543fa04eb30b4?s=96&d=identicon&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e5fcf26bedbd04dc20896c519164a13fe69c6913f5830d7db51543fa04eb30b4?s=96&d=identicon&r=g","caption":"EFE"},"sameAs":["http:\/\/efe.com"],"url":"https:\/\/efecomunica.efe.com\/en\/author\/efedesarrollo\/"}]}},"jetpack_featured_media_url":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","jetpack_likes_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/pcEg1r-Eyp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/posts\/155893","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/users\/198164071"}],"replies":[{"embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/comments?post=155893"}],"version-history":[{"count":3,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/posts\/155893\/revisions"}],"predecessor-version":[{"id":155928,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/posts\/155893\/revisions\/155928"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/media\/48434"}],"wp:attachment":[{"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/media?parent=155893"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/categories?post=155893"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/tags?post=155893"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}